Manaav Mehta1, Jeremy Louissaint2, Neal S Parikh3, Michelle T Long4, Elliot B Tapper5. 1. University of California at Los Angeles, Los Angeles. 2. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor. 3. Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Cornell University, Ithaca, NY. 4. Section of Gastroenterology, Boston University School of Medicine, Boston, Mass. 5. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor. Electronic address: etapper@umich.edu.
Abstract
BACKGROUND: Frailty is an important contributor to morbidity and mortality in chronic liver disease. Understanding the contributors to frailty has the potential to identify individuals at risk for frailty and may potentially provide targets for frailty-modifying interventions. We evaluated the relationship among cognitive function, inflammation, and sarcopenia and frailty. METHODS: Using cohorts from the Framingham Heart Study (2011-2014), we evaluated for factors associated with frailty. Exposures included cognitive tests (combined Trails A/B test, Animal Naming Test, and combined Digit Span Forward/Backward test), inflammation (interleukin-6 and tumor necrosis factor receptor II), and sarcopenia (creatinine-to-cystatin C ratio). We performed linear and logistic regression to identify the relationship between these exposures and the Liver Frailty Index (LFI). RESULTS: The study population (N = 1208) had a median age of 70 years, was 56% female, and 48.5% had evidence of liver disease. The combined Trails A/B test (β 0.05, P < .001), creatinine-to-cystatin C (β -0.17, P = .006), and both inflammatory markers, interleukin-6 levels (β 0.16, P = .002) and tumor necrosis factor receptor II (β 0.21, P = .04), were independently associated with the LFI. Using an LFI cutoff of ≥4.5 to define frailty, Trails A/B (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.37), Animal Naming Test (OR 0.64, 95% CI 0.42-0.97), sarcopenia (OR 0.10, 95% CI 0.01-0.73), and interleukin-6 (OR 4.99, 95% CI 1.03-15.53) were all associated with frailty. Although liver disease did not modify the relationship between the LFI and the Trails A/B test, interleukin-6 was significantly associated with the LFI only in the presence of liver disease. CONCLUSIONS: Cognitive performance, inflammation, and sarcopenia, each highly prevalent in cirrhosis, are associated with the LFI in this population-based study of persons without cirrhosis. Further research is warranted for interventions aiming to prevent frailty by tailoring their approach to the patient's underlying risk factors.
BACKGROUND: Frailty is an important contributor to morbidity and mortality in chronic liver disease. Understanding the contributors to frailty has the potential to identify individuals at risk for frailty and may potentially provide targets for frailty-modifying interventions. We evaluated the relationship among cognitive function, inflammation, and sarcopenia and frailty. METHODS: Using cohorts from the Framingham Heart Study (2011-2014), we evaluated for factors associated with frailty. Exposures included cognitive tests (combined Trails A/B test, Animal Naming Test, and combined Digit Span Forward/Backward test), inflammation (interleukin-6 and tumor necrosis factor receptor II), and sarcopenia (creatinine-to-cystatin C ratio). We performed linear and logistic regression to identify the relationship between these exposures and the Liver Frailty Index (LFI). RESULTS: The study population (N = 1208) had a median age of 70 years, was 56% female, and 48.5% had evidence of liver disease. The combined Trails A/B test (β 0.05, P < .001), creatinine-to-cystatin C (β -0.17, P = .006), and both inflammatory markers, interleukin-6 levels (β 0.16, P = .002) and tumor necrosis factor receptor II (β 0.21, P = .04), were independently associated with the LFI. Using an LFI cutoff of ≥4.5 to define frailty, Trails A/B (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.37), Animal Naming Test (OR 0.64, 95% CI 0.42-0.97), sarcopenia (OR 0.10, 95% CI 0.01-0.73), and interleukin-6 (OR 4.99, 95% CI 1.03-15.53) were all associated with frailty. Although liver disease did not modify the relationship between the LFI and the Trails A/B test, interleukin-6 was significantly associated with the LFI only in the presence of liver disease. CONCLUSIONS: Cognitive performance, inflammation, and sarcopenia, each highly prevalent in cirrhosis, are associated with the LFI in this population-based study of persons without cirrhosis. Further research is warranted for interventions aiming to prevent frailty by tailoring their approach to the patient's underlying risk factors.
Authors: Erin F Barreto; Janelle O Poyant; Hongchuan H Coville; Ross A Dierkhising; Cassie C Kennedy; Ognjen Gajic; Erin M Nystrom; Naoki Takahashi; Michael R Moynagh; Kianoush B Kashani Journal: Clin Nutr Date: 2018-06-08 Impact factor: 7.324
Authors: Jennifer C Lai; Christopher J Sonnenday; Elliot B Tapper; Andres Duarte-Rojo; Michael A Dunn; William Bernal; Elizabeth J Carey; Srinivasan Dasarathy; Binita M Kamath; Matthew R Kappus; Aldo J Montano-Loza; Shunji Nagai; Puneeta Tandon Journal: Am J Transplant Date: 2019-05-08 Impact factor: 8.086
Authors: Tze Pin Ng; Liang Feng; Ma Shwe Zin Nyunt; Lei Feng; Mathew Niti; Boon Yeow Tan; Gribson Chan; Sue Anne Khoo; Sue Mei Chan; Philip Yap; Keng Bee Yap Journal: Am J Med Date: 2015-07-06 Impact factor: 4.965
Authors: Allyson Hart; Terri L Blackwell; Misti L Paudel; Brent C Taylor; Eric S Orwoll; Peggy M Cawthon; Kristine E Ensrud Journal: J Gerontol A Biol Sci Med Sci Date: 2017-07-01 Impact factor: 6.053
Authors: P Van Epps; D Oswald; P A Higgins; T R Hornick; H Aung; R E Banks; B M Wilson; C Burant; S Graventstein; D H Canaday Journal: Immun Ageing Date: 2016-10-19 Impact factor: 6.400
Authors: Leonard Kaps; Lejla Lukac; Maurice Michel; Wolfgang Maximilian Kremer; Max Hilscher; Simon Johannes Gairing; Peter R Galle; Jörn M Schattenberg; Marcus-Alexander Wörns; Michael Nagel; Christian Labenz Journal: Diagnostics (Basel) Date: 2022-04-24
Authors: Ezequiel Mauro; Juan Manuel Diaz; Lucrecia Garcia-Olveira; Juan Carlos Spina; Lorena Savluk; Fernanda Zalazar; Julia Saidman; Martin De Santibañes; Juan Pekolj; Eduardo De Santibañes; Gonzalo Crespo; Juan G Abraldes; Adrían Gadano Journal: Hepatol Commun Date: 2022-03-03